osteoclastic bone metastases, Paget's disease, and in the future probably also in osteoporosis [1,2]. Further, Background. Clodronate is a bisphosphonate used in the treatment of hypercalcaemia of various aetiologies. clodronate might also be of benefit in therapy for patients with uraemic bone disease, the indications for The major route of elimination of clodronate is renal excretion. The aim of the study was to derive data for its use being hypercalcaemia related to the increased release of calcium from bone, excessive elevation of the adjustment of dosage in haemodialysis patients. Methods. The pharmacokinetic parameters describing bone turnover, and extraosseus calcification [3][4][5].
Introduction

Experimental protocol
Clodronate is a bisphosphonate which is used in the treatment of hypercalcaemia of various aetiologies, session. Immediately after the completion of clodronate an intravenous infusion time of 1 h. The computational algorithm used was the weighted least squares with a infusion haemodialysis was started. All patients were dialysed weighting factor 1/y. The results are given as means±SD. on Fresenius 2008 E volumetric haemodialysis machines with The AUC −1−i was a cumulative area under the concentra-1.7 m2 cellulose acetate hollow-fibre dialysers. Blood flow tion-time curve calculated with the linear trapezoidal rule was set at 250-300 ml/min, dialysis solution flow 500ml/min. from the beginning of the drug infusion (−1 h) to the desired The bicarbonate-buffered dialysate contained 1.25 mmol/l time point. The amount of the drug excreted in dialysate calcium. The duration of the dialysis session was 4 h in seven (E D ) was the product of volume×AUC for dialysate. The patients and 5 h in three.
excretion in urine (E U ) was the volume×drug concentration Blood samples were taken during the study according to for urine. Elimination clearance by haemodialysis (CL D ) and the following schedule: one before the start of the infusion kidneys (CL R ) alone were calculated by dividing respectively (pre-drug), one immediately after the cessation of the infu-E D and E U by serum AUC for the desired time periods. The sion, and thereafter at 30 min, 1, 2, 3, 4, (5 h in patients with terminal elimination half-life in serum (t 1/2term ), and the 5-h dialysis session), 7, 12 and 24 h after the infusion. The volume of distribution ( V d ) were extrapolated by means of blood samples were drawn from the opposite arm to the regression line of serum drug concentrations during the infusion site. Whole-blood samples were centrifuged within course of time. These parameters, and the volume of distribu-30 min (1500 g, 10 min); the serum was separated into duplic-tion in steady state ( V ss ) and the terminal serum clearance ate polypropylene tubes, immediately frozen and stored at (CL term ) were determined on the dialysis day from serum −20°C until assayed. In patients with residual diuresis urine data from 4 h (or 5 h in patients with 5-h dialysis session) to was collected from the beginning of the drug infusion up to 24 h after cessation of drug infusion, i.e. from serum drug 24 h after the infusion and the volumes measured. Dialysate levels after haemodialysis was discontinued, with the Topfit samples were taken during the dialysis session at the same program for non-compartmental analysis. In each subject, time as blood samples. Urine and dialysate samples were the 2-and 3-compartment disposition models were also stored similarly to serum. Plasma levels of intact parathyroid tested, but generally they were not found to be better hormone (PTH ) were measured to assess the severity of applicable to the present dialysis patients than the nonsecondary hyperparathyroidism.
compartmental analysis, especially, since the rapid drug removal during haemodialysis could not be simulated with The patients were studied twice in a crossover manner on 2-or 3-compartment model and serum drug concentrations dialysis and non-dialysis days according to the same protocol were monitored for only 24 h (see concentration curve on with at least 3 weeks' interval. On the non-dialysis day the dialysis day, Figure 1 ). patients remained in the bed for the respective time period.
On the non-dialysis day the same calculation methods were used and the data were derived from the same time
Analytical methods
points as on dialysis day, since only so the kinetic parameters were considered to be comparable to the parameters calcuDisodium clodronate in serum, urine and dialysis solution lated on dialysis day. The theoretical elimination half-life for samples were analysed by capillary gas chromatography with the drug, if this had been removed by haemodialysis only (t 1/2D ), was calculated from the formula t 1/2D =ln 2×V d /CL D. mass-selective detection (HP-5970, column material HP-ultra Non-renal, non-dialysis elimination half-life in serum II ). Details of the analytical methods have been decribed in (t 1/2NRD ) was calculated from the formula t 1/2NRD =ln our previous report [10] The pharmacokinetic parameters (mean±SD) on dialysis and non-dialysis days are shown in Table 2 . The cumulative excretion of clodronate into dialysate is presented in Figure 2 . As shown in Table 2 , 159 mg clodronate of the infused 300 mg (53%) was excreted into dialysate within 4 or 5 h. Total serum clearance during the dialysis session (CL tot ), clearance by haemodialysis only (CL D ), renal clearance (CL R ), non-renal, non-dialysis clearance (CL NRD ), terminal half-life (t 1/2term ), and non-renal, non-dialysis half-life (t 1/2NRD ) in each patient on the dialysis day and on the non-dialysis day are summarized in Table 3 . CL D (87.8±16.2 ml/min) accounted for 84% of CL tot (104±11.9 ml/min). Four patients had residual diuresis ranging from 200 to 1000 ml/25 h. Even in these patients the influence of residual renal clearance on CL tot was insignificant except in one patient (no. 6, Table 3 ). or kidneys. The greatest CL NRD was observed in those patients with most severe hyperparathyroidism, their intact plasma PTH levels being more than 10 times day on an average 161 mg (54%) of the drug was removed by dialysis and kidneys, and on the higher than the upper reference limit of PTH in healthy subjects. There was a positive correlation between non-dialysis day 12.2 mg (4%) via the kidneys.
Correspondingly, 61 mg (20%) and 119 mg (40%) of CL NRD and intact PTH (r=0.87, P=0.001, see Figure 3 ). the drug was not yet either excreted or deposited into its peripheral storages at 24 h ( Table 4) . At 24 h after stopping the infusion, on the dialysis Table 3 . Diuresis, total elimination clearance during the dialysis session (CL in patients with end-stage renal disease [5, [14] [15] [16] , and only one report on the removal of clodronate by haemodialysis [5] . In a study by Biegel et al. 35% of injected clodronate was removed into dialysate during a 4-h haemodialysis [11] . The results of the present study accord with this finding. According to the pharmacokinetic parameters, 53% of the infused single dose was removed via the dialysate during 4-5 h, and the clearance by dialysis accounted for up to 84% of the total serum clearance of the drug during the haemodialysis session. In our previous study we found that in healthy subjects about two-thirds of the injected dose of clodronate is excreted into urine in 24 h [10] . Total clearance of clodronate in haemodialysis patients on a dialysis day (104±11.9 ml/min) was not very different from that previously observed in healthy subjects (120 ml/min) [10] . During the dialysis day the removal of clodronate clodronate and plasma intact PTH concentration on non-dialysis via dialysis accounted for 84% of total clearance. In day in 10 haemodialysis patients receiving 300 mg of clodronate all patients but one elimination via the kidneys was of disodium intravenously for 60 min.
no significance. The portion of non-renal, non-dialysis clearance ranged from 5.7 to 30.9% (mean 14.6%).
Discussion
Because of the continuous dialysate flow (500 ml/min) the concentration gradient of clodronate between serum and haemodialysis fluid remained quite high, When clodronate is used in the treatment of hypercaland clodronate seemed to be well diffused into the caemia in patients with impaired renal function, the dialysate through the dialysis membrane. The high dose should be adjusted according to the residual renal clearance of the drug via haemodialysis can be attribfunction [9, 10] . Clodronate or other bisphosphonates uted to the fact that clodronate is markedly hydrophilic might also be useful in dialysis patients in the treatment and has relatively low molecular weight (mw=244.89), of secondary hyperparathyroidism with high boneand the major fraction of the drug (about 65%) is not turnover, since bisphosphonates inhibit PTH-mediated bound to serum proteins [8, 18] . Thus, a standard bone resorption [4] . Combination of bisphosphonhaemodialysis session removes clodronate effectively ate with vitamin D would be reasonable in view of from the circulation. This is probably not the case with the calcium-lowering effect of bisphosphonates, since those bisphosphonates that are bound to serum prothe development of hypercalcaemia often prevents teins to a greater extent than clodronate [19] . adequate vitamin therapy [4] . However, clodronate
Similarly to other bisphosphonates, clodronate is and other related compounds should not be used in avidly retained by the skeleton. In general, about patients with low-turnover bone disease or with defect-20-50% of clodronate is ultimately located in bone ive mineralization of bone on account of the risk of [1, 2, 17, 18] . The other possible non-renal routes for aggravating the bone disease [4, [12] [13] .
There are few studies on the use of bisphosphonates elimination are deposition in the liver and spleen, , rest of the drug neither excreted nor deposited at 4(5*) and 24 h. *In three patients the duration of dialysis was 5 h. **Calculated from the beginning of clodronate infusion (−1 h).
